Results for tag: "Aryl Hydrocarbon Receptor"

The Aryl Hydrocarbon Receptor (AhR) is a transcription factor that plays a role in the regulation of a variety of physiological processes, including drug metabolism, inflammation, and immune response. It is also a target for drug development in a variety of therapeutic areas, including oncology, immunology, and metabolic diseases. AhR-targeted drugs are being developed to treat a range of diseases, including cancer, autoimmune diseases, and metabolic disorders. In oncology, AhR-targeted drugs are being developed to target tumor cells and to modulate the immune system to fight cancer. In immunology, AhR-targeted drugs are being developed to modulate the immune system to treat autoimmune diseases. In metabolic diseases, AhR-targeted drugs are being developed to modulate the metabolism of lipids and glucose. Companies in the AhR market include AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more